A detailed history of Bank Of America Corp transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 121,614 shares of INZY stock, worth $366,058. This represents 0.0% of its overall portfolio holdings.

Number of Shares
121,614
Previous 140,022 13.15%
Holding current value
$366,058
Previous $624,000 1.92%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.31 - $6.0 $79,338 - $110,448
-18,408 Reduced 13.15%
121,614 $636,000
Q2 2024

Aug 14, 2024

BUY
$4.33 - $7.31 $346,954 - $585,735
80,128 Added 133.78%
140,022 $624,000
Q1 2024

May 15, 2024

SELL
$4.14 - $7.66 $57,148 - $105,738
-13,804 Reduced 18.73%
59,894 $458,000
Q4 2023

Feb 14, 2024

BUY
$2.71 - $4.5 $49,308 - $81,877
18,195 Added 32.78%
73,698 $313,000
Q2 2023

Aug 14, 2023

BUY
$4.93 - $6.74 $216,698 - $296,256
43,955 Added 380.63%
55,503 $309,000
Q1 2023

May 12, 2023

BUY
$1.3 - $5.73 $5,775 - $25,458
4,443 Added 62.53%
11,548 $66,000
Q4 2022

Feb 10, 2023

BUY
$1.05 - $2.82 $4,386 - $11,781
4,178 Added 142.74%
7,105 $7,000
Q3 2022

Nov 14, 2022

BUY
$2.57 - $5.45 $7,504 - $15,914
2,920 Added 41714.29%
2,927 $8,000
Q2 2022

Aug 12, 2022

SELL
$3.2 - $5.96 $21,248 - $39,574
-6,640 Reduced 99.89%
7 $0
Q1 2022

May 16, 2022

SELL
$3.87 - $7.55 $20,147 - $39,305
-5,206 Reduced 43.92%
6,647 $28,000
Q4 2021

Feb 08, 2022

BUY
$5.58 - $11.5 $64,538 - $133,009
11,566 Added 4029.97%
11,853 $81,000
Q3 2021

Nov 15, 2021

SELL
$11.12 - $19.4 $24,653 - $43,009
-2,217 Reduced 88.54%
287 $4,000
Q2 2021

Sep 13, 2021

BUY
$15.19 - $21.2 $38,035 - $53,084
2,504 New
2,504 $43,000

Others Institutions Holding INZY

About Inozyme Pharma, Inc.


  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $121M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.